Introduction {#s0005}
============

Improving modifiable risk factors for the prevention and management of chronic diseases like type-2 diabetes (T2D) can be cost-effective. For example, results from the Diabetes Prevention Program suggest the incremental costs of the intensive lifestyle intervention were largely offset by the costs incurred through medications, blood glucose monitoring and hospitalization (inpatient and outpatient) ([@bb0045]). More recently, the highly intensive Look AHEAD lifestyle intervention found fewer hospitalizations, lower medication use and lower overall health care costs over 10 years of follow-up despite not achieving the trial\'s primary target of reduced cardiovascular related morbidity and mortality among adults with T2D ([@bb0065]).

Indeed, the management of diabetes is complex and expensive and is best supported through an interdisciplinary team-based approach ([@bb2015]). Healthy eating and active living are key strategies for diabetes self-management, requiring varying support depending on the stage (i.e., more support at the time of diagnosis). Such self-management support requires substantial resource allocation, largely delivered in primary care settings ([@bb0010]); knowing this however, few primary care-based studies have examined the economics of supporting self-management behaviors, including active living ([@bb0090]). Health care utilization and costs appear to be higher among adults with T2D who do not achieve recommended levels of physical activity ([@bb0105]), suggesting that supporting the achievement of physical activity guidelines may offer financial benefit.

Sufficient evidence exists to suggest that physical activity programs for T2D in primary care can be effective for increasing daily physical activity ([@bb0100], [@bb0140]). We recently completed the Healthy Eating and Active Living for Diabetes in Primary Care Networks (HEALD) trial where we demonstrated that an exercise specialist-led lifestyle program for adults with recently diagnosed T2D in primary care, was effective for increasing daily steps compared to usual care controls ([@bb0080]), along with a comprehensive evaluation of the intervention ([@bb0145]). Our objective here was to consider the cost-effectiveness of the HEALD intervention versus usual care in a primary care setting.

Methods {#s0010}
=======

Setting and sample {#s0030}
------------------

The complete study and evaluation design have been previously reported ([@bb0080], [@bb0075], [@bb0145]). Patients recently diagnosed with T2D were recruited from four Primary Care Networks (PCNs) in Alberta, Canada. All PCNs are stand-alone physician-lead corporations established to support family physicians through allied professionals, including: Chronic Disease Management Nurses, Registered Dieticians, Pharmacists, Health Promotion and Prevention Coordinators and Exercise Specialists.

For recruitment, a patient registry that included information about the patient\'s medical management was used to identify and recruit study participants through each participating PCN. An endorsement letter from each PCN was mailed to the potential participant by staff located at each PCN ([@bb0075]). Only adults (≥ 18 years) who previously received basic diabetes education and were able to read, understand and converse in English were eligible. Those with significant self-reported cardiovascular history on pre-screening (i.e., fainting/dizziness on physical exertion, angina pain, pacemaker, surgery) and current depressive symptoms were also excluded.

All participants were asked to provide their personal health number (PHN) and consent to obtain healthcare utilization data. All data provided was de-identified. The HEALD study was approved by the Health Research Ethics Board at the University of Alberta; ID: Pro00008427. We enrolled 198 people (102 intervention and 96 control) between January 2010 and September 2012, though, for this cost--effectiveness analysis, 186 consented for linkage with health care administrative data (94 intervention and 92 control).

Intervention and control {#s0035}
------------------------

Eligible participants were allocated using an interrupted time series design ([@bb0085]). The intervention group participated in a 24-week pedometer-based walking program led by a trained Exercise Specialist at each PCN. All four Exercise Specialists responsible for implementing HEALD had a four-year university degree in Kinesiology/Human Kinetics/Physical Education and professionally certified by the Canadian Society for Exercise Physiology ([@bb0025]). Two of the four Exercise Specialists were employed by their respective PCN, one was seconded from another provincially funded health organization while the third was a casual PCN employee.

For the first 12-weeks of the intervention two group sessions lasted approximately 1 h where participants were provided a pedometer, a logbook and a theory-based resource manual to support individualized goal setting, monitoring, self-efficacy and social support. Participants set their own daily step goals (i.e., a prescribed daily step goal such as 10,000 steps/day was not a component of the program) ([@bb0075]).

After the first 12 weeks, participants were encouraged to walk faster for 30 min 3 days/week for 12 weeks, and to maintain their daily volume step goal (e.g., 7500 steps/day) from the first phase. Two group sessions took place, giving similar resources, but with the behavioral target for brisk walking using a stopwatch. Participants walked on an indoor walking track at a local recreational facility for \~ 30 min, supervised and coached by the exercise specialist, to support the experiential component during both phases.

Those allocated to the usual care control group received a pedometer at baseline with no additional instructions around its use and received usual care during the same 24-week study follow-up period.

Diabetes-related outcomes {#s0040}
-------------------------

Fasting capillary blood samples were collected at point-of-care to assess hemoglobin A1c (DCA Vantage), lipid profile, and glucose (Cholestech, LDX), and resting heart rate and blood pressure were also collected (BPTru). Anthropometric measurements including weight, height, and waist circumference were completed and body mass index (BMI) was calculated. All measures were collected at baseline, 3 and 6 months.

Resource use and cost estimates {#s0045}
-------------------------------

Intervention costs included activity time and training of the Exercise Specialists, administrative support personnel, recreation facilities, supplies, equipment, and PCN overhead. Personnel cost estimates were based on the expected group session time, individual counseling and training. Unit costs, including vacation/holiday pay and benefits, were obtained from collective agreements. Overhead cost was assumed 5%, representing the marginal impact on the PCNs. Other component estimates were based on actual costs.

For health care resource use, only direct costs of physician services, hospital outpatient visits and hospital inpatient admissions were included, since the analysis was conducted from a public payer perspective. Since the analytical horizon was less than one year, discounting was not required. All costs were adjusted to 2011 Canadian prices because participant recruitment and follow-up occurred over three years (2009--2012).

To estimate costs we obtained participant (i.e., HEALD and usual care) specific utilization data for physician services, hospital outpatient clinics (including the emergency department) and hospital inpatient services for six months prior to and six months after the completion of the intervention. The provincial government (Alberta Health) uses a fee-for-service system to pay for physician services, based on a standard schedule. For all physician services included in this study, the 2011 schedule was used ([@bb0005]). The cost estimates of hospital services were the product the relative cost weight of each service and \$6371, the 2011 Alberta cost per weighted case ([@bb0015]). The relative cost weights were based on separate case-based grouping. Outpatient weights were scaled so that the cost per weighted inpatient admission could be applied to both outpatient and inpatient events ([@bb0020]). The cost estimates of inpatient and outpatient services include drug costs, however, prescription medication costs purchased from community pharmacies were excluded. The cost of operational overhead was included in the estimates for all services.

Health outcome (effectiveness) {#s0050}
------------------------------

The primary outcome was physical activity determined by pedometers; average daily steps, measured and recorded by participants over three days including one weekend day ([@bb9000]), and collected at baseline, 3 and 6 months.

Cost effectiveness analysis (CEA) {#s0055}
---------------------------------

Incremental cost is the difference in the average cost per participant between study groups and the incremental health effect, here, the difference in the average number of steps per participant between study groups. We used a regression framework to adjust incremental cost and health outcome estimates for baseline covariates. Incremental cost was adjusted for differences in 6-month pre-enrolment health care cost and body mass index (BMI). Incremental steps were adjusted for differences in baseline average steps, BMI, age and sex. The incremental cost--effectiveness ratio (ICER) was expressed in 000s of steps, thus representing the additional cost per 1000 additional steps achieved.

In general, cost-effective interventions: cost less (the incremental cost is negative) and are more effective (the incremental health effect is positive), or cost more and are more effective, but society is willing to pay for the additional cost ([@bb0050]). In the latter scenario, the ICER is less than a threshold level that reflects the amount society is willing to pay for an additional unit of health outcome.

Stochastic analysis of uncertainty {#s0060}
----------------------------------

To account for uncertainty due to sampling variation, we used a non-parametric bootstrapping analysis to generate a scatter plot of incremental cost and health effect on the cost--effectiveness plane ([@bb0050]). Based on that generated distribution, a cost--effectiveness acceptability curve (CEAC) was derived, indicating the probability of the intervention being cost-effective at various levels of society\'s willingness to pay per an additional 1000 steps.

We estimated a cost--effectiveness threshold for the intervention in order to interpret the CEAC, since we know of no established benchmark cost--effectiveness threshold for additional steps/day. Following a recently published method, the threshold was estimated as the ratio of average cost to average health effect using the sample data of the control group ([@bb0070]). This threshold reflects the opportunity cost, relating to the health outcome foregone, by the reallocation of resources required to implement the intervention ([@bb0030]).

Statistical analyses {#s0065}
--------------------

All statistical analyses were performed using R version 3.0.3 \[R Foundation for Statistical Computing, Vienna, Austria\]. For analyses based on the original sample the Rcmdr package for R, version 2.0-4 \[Fox, Bouchet-Valat; Hamilton ON, Canada\] was used. Non-parametric bootstrap analysis was conducted with the Boot package for R \[Canty, Ripley; Hamilton ON, Canada\]. Filemaker Pro Advanced version 13.0 v3 \[Filemaker Inc., Santa Clara, USA\] was used for general data management.

Missing data {#s0070}
------------

For the 186 participants, only about 3% of the data was missing, and related almost entirely to the primary outcome (steps). Since the proportion of missing data was so small, the last observation carried forward was used to impute missing observations at 6 months and mean value substituted any baseline observations.

Results {#s0015}
=======

The main results have been previously reported ([@bb0080]). Briefly, at baseline the mean age was 59.5 (SD 8.3) years, A1c 6.8% (SD 1.1), 50% women, BMI 33.6 kg/m^2^ (SD 6.5), systolic pressure 125.6 mm Hg (SD 16.2) and the average daily steps were 5879 (SD 3130). Daily pedometer determined steps increased for the intervention compared to usual care control at 3-months (1292 \[SD 2698\] vs. 418 \[SD 2458\]) and 6-months (1481 \[SD 2631\] vs. 336 \[SD 2712\]; adjusted p = 0.002).

Intervention participants used fewer health resources both prior to and after enrolment in the study, although no differences were statistically significant ([Table 1](#t0005){ref-type="table"}). HEALD cost \$340 per participant, with nearly 60% related to intervention activities and training of the exercise specialists. With the exception of the intervention cost, intervention participants incurred less cost in all categories (physician, out- and in-patient costs) compared to the controls during the follow-up period. The unadjusted mean difference in total cost (intervention plus health care utilization) between groups was insignificant (\$4). However, excluding the intervention cost, average cost per intervention participant would be \$336 less than for control patients. HEALD participants also incurred fewer costs in the pre-enrollment period. After adjusting for pre-enrolment cost and BMI, the adjusted incremental cost was \$102 ([Table 2](#t0010){ref-type="table"}), although not statistically significant. Higher levels of pre-enrolment cost and BMI were significantly associated with higher follow-up costs.

In terms of health outcome, intervention participants were more active at 6 months, by an adjusted incremental rate of 919 steps, compared with an unadjusted increment of 393 steps ([Table 3](#t0015){ref-type="table"}). In both the original sample and the bootstrapped analysis the incremental health effect was statistically significant ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}).

Based on the adjusted incremental estimates, the ICER was \$111 per 1000 daily steps ([Table 3](#t0015){ref-type="table"}). The joint distribution of the incremental cost and health effect is shown in [Fig. 2](#f0010){ref-type="fig"}, with 69% of the bootstrap replicates located in quadrant I (greater cost, better health outcome) and 30% in quadrant IV, consistent with dominance by the intervention (lower cost, better health outcome). The CEAC ([Fig. 1](#f0005){ref-type="fig"}) shows that if society is willing to pay a greater amount for additional steps, the likelihood that the intervention is cost-effective rises steadily to about 97% when willingness-to-pay (WTP) reaches \$1000. Based on control group results, we estimated the implied cost-effective threshold to be \$176 per additional 1000 steps (point A). At that level, the probability that intervention would be cost-effective is about 60%. The point estimate of the ICER is \$111 (point B), clearly less than the estimated threshold.

Discussion {#s0020}
==========

Our analysis suggests HEALD may be a cost-effective approach to increasing physical activity in adults with T2D. We conservatively estimated the total intervention cost to be \$340 per participant over the 6-month follow-up period. Including intervention costs and health care expenses, the difference in total costs between groups was \$102 per participant. Intervention participants increased their physical activity by almost 1000 steps per day, at an incremental cost of \$111 compared with usual care.

A common alternative outcome used in economic evaluations is the quality adjusted life years (QALYs) ([@bb0115]). To our knowledge, only one study examined the cost-effectiveness of a lifestyle program in a Canadian T2D population. Using data from the DARE trial ([@bb0120]), [@bb0040] found that the incremental cost per QALY gained was lowest for a combined aerobic and resistance exercise program against all comparators (i.e., no program, aerobic only and resistance only), concluding that a combined exercise program was most cost-effective for adults with T2D. Our results did not consider QALYs, but rather objectively assessed physical activity behavior (pedometer determined steps), and compared the total costs of both groups.

Given that walking and physical activity are associated with many health benefits ([@bb0140]), QALYs restrict the broad assessment of intervention impacts ([@bb0115]), limiting the true value of increasing physical activity. [@bb0095] comment that theoretically QALYs provide an objective threshold, however, in reality, different approaches provide different values, each based on different assumptions, inferences and contexts. It is impossible to find a single threshold to truly compare interventions ([@bb0095]). In examining cost per daily steps, we provide a unique perspective that has not been previously presented in any chronic disease population. As a novel approach, there is no accepted benchmark or threshold, and it is therefore up to the policymaker to determine the societal value of our outcome, appropriate to the setting and population.

Physical activity interventions can be cost-effective. In their systematic review, [@bb0150] reported comparable cost effectiveness outcomes across a broad range of physical activity interventions by calculating MET-hour gained per day per individual reached. Unlike QALYs, Wu et al., state that this approach accounts for the major parameters of physical activity, including frequency, duration and intensity. In terms of program delivery, they reported that individualized behavior change and social support programs, much like HEALD, were the least cost-effective interventions for increasing daily physical activity. However, they reported that these programs demonstrated greater effect sizes, adding 35%--43% of the guideline-recommended physical activity for adults ([@bb0150]). Because they are not only effective, but also costly, these types of programs might be best suited for targeted groups requiring additional support in self-management, like people with T2D.

A recent meta-analysis of randomized controlled trials using pedometers in people with T2D found an increase in daily steps of 1822 across 7 studies (861 participants; 95% confidence interval (CI): 751 to 2894 steps/day) but no improvements in glycemic control ([@bb0110]). Some have suggested that an increase in steps/day of 4000 baseline may be a clinically relevant threshold for improving glycemic control in T2D ([@bb0130]). Observational data from the NAVIGATOR trial and AusDIAB study suggests that increases in steps/day above baseline between 1000--2500 reduce the risk of dysglycemia and other cardiovascular related events over 5 years of follow-up among those with a higher cardiometabolic risk profile ([@bb0055], [@bb0155]). Hence, we argue that although a 1000 steps/day increase might seem low, the increase in daily steps reported here may have behavioral, clinical, and economic relevance.

Our results are important for questions around program implementation and sustainability. It is true that 'pedometers cost buttons' ([@bb0115]), but good quality pedometers alone are insufficient to support increases in daily ambulatory activity over the longer term. Pedometers have been likened to a computer without an operating system; that is, providing a pedometer without structured support that incorporates behavioral theory (i.e., goal setting and tracking with a degree of social support) renders the device insufficient for behavior change ([@bb9000]). HEALD was designed to include behavioral theory and experiential learning in a hospitable environment (a recreational facility with a walking track) and the control group received a pedometer without instruction or support. Hence, the costs beyond simply providing patients with pedometers must be considered by primary care providers to successfully implement a program to increase daily physical activity.

Moreover, HEALD was designed using group sessions, helping to reduce the costs per patient that incur with face-to-face counseling ([@bb0140]). Once well established, more people per session could register, therefore reducing per participant costs. More research is needed to determine the optimal class size for effective and efficient delivery. As well, training can be considered an initial start-up cost, reducing overall cost over time. Regarding program sustainability, by choosing an everyday outcome measure (i.e. steps), continuous program and individual evaluation is possible with minimal resources, extra training and other costs and thus potentially contributing towards long-term program adoption ([@bb0090]).

This analysis has various strengths. The lack of current literature regarding economic evaluation of physical activity interventions and especially controlled trials, attests to the need of this type of analysis. We were able to capture the health care costs of both groups. As well, over 93% of the original participants consented for administrative data linking, maintaining our intended sample size and controlling any differences between the groups of consenting participants. Despite the strengths we have outlined we acknowledge that this study has some weaknesses. Firstly, we used steps/day as our effectiveness measure and because steps are only one component of total daily physical activity the use of an accelerometer may have provided a better objective estimate of daily physical activity across both groups. Nevertheless, steps were the intended target of the intervention. Secondly, we limited our follow-up to a one-year time horizon and hence we have constrained the potential to estimate the long-term impact of the HEALD intervention. Lastly, economic analyses drawn from a healthcare setting where all patients have universal healthcare coverage may limit the generalizability of our findings. For example, one exercise specialist to manage hundreds if not thousands of diabetes patients in this type of setting requires consideration given that they may have other responsibilities (e.g., other patient populations).

In a time of priority shifting and results-based budgeting, without using QALYS, it is difficult to compare the cost-effectiveness of HEALD to other health interventions. Though our analysis is unique, it will take extra effort to present findings to policymakers and reinforce the longer-term impacts and overall health benefits of this walking program. This approach also considers the limitation of the short-term nature of our study. While we considered the cost of hospital, outpatient and physician services, we were unable to estimate differences in costs of lab tests or medications between groups, although given the short-term follow-up, and lack of change in clinical parameters ([@bb0080]), it is unlikely that these differed between study groups.

Conclusion {#s0025}
==========

Health Eating and Active Living for Diabetes (HEALD) was an effective program in increasing daily steps among people with type-2 diabetes in primary care, which over a lifetime, may have worthwhile health benefits. Our economic analysis suggests that the intervention may be cost-effective.
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###### 

Resource utilization and cost by study group[a](#tf0005){ref-type="table-fn"}[b](#tf0010){ref-type="table-fn"}.

                                            Pre-enrolment period   Follow-up period                                                       
  ----------------------------------------- ---------------------- ------------------ ----------------------- ------------- ------------- -----------------------
  *Resource utilization*                                                                                                                  
  Physician visits                          8.1 (6.0)              10.4 (11.4)        − 2.3 (− 0.36, 4.9)     7.0 (6.0)     7.8 (6.6)     − 0.8 (− 1.0, 2.6)
  Outpatient clinic visits                  2.5 (5.1)              3.1 (4.4)          − 0.6 (− 0.8, 1.9)      1.4 (2.6)     2.3 (4.1)     − 0.9 (− 0.1, 1.9)
  Inpatient admissions                      0.02 (0.15)            0.08 (0.27)        − 0.06 (− 0.01, 0.12)   0.01 (0.10)   0.02 (0.15)   − 0.01 (− 0.03, 0.04)
                                                                                                                                          
  *Cost*[c](#tf0015){ref-type="table-fn"}                                                                                                 
  Intervention                                                                                                340 (0)       0 (0)         340 (0)
  Physician                                 586 (549)              784 (1043)         − 198 (− 44, 440)       469 (526)     573 (613)     − 104 (− 62, 269)
  Outpatient                                494 (910)              706 (1230)         − 212 (− 102, 525)      330 (592)     477 (761)     − 147 (− 51, 345)
  Inpatient                                 96 (751)               401 (1605)         − 305 (− 60, 670)       37 (340)      122 (913)     − 85 (− 117, 287)
  Total                                     1176 (1619)            1891 (3240)        − 715 (− 31, 1460)      1176 (1248)   1172 (1844)   4 (− 461, 453)

Data were collected between January 2010 and September 2012 in Alberta, Canada.

All values within study groups are expressed as average per participant (sd) based on the original sample.

For differences between study groups 95% confidence intervals are shown in parentheses.

2011 Canadian dollars.

###### 

Results for cost and health outcome regressions[a](#tf0020){ref-type="table-fn"}.

  Independent variables    Coefficient estimates (t-statistics)           
  ------------------------ ---------------------------------------------- --------------------------------------------------
  Study group (1/0)        102 (0.47)                                     919[†](#tf0025){ref-type="table-fn"} (2.37)
  Pre-enrolment cost       0.21[§](#tf0035){ref-type="table-fn"} (5.06)   
  Body mass index (BMI)    33.7[†](#tf0025){ref-type="table-fn"} (2.00)   − 76.2[†](#tf0025){ref-type="table-fn"} (− 2.51)
  Baseline average steps                                                  0.69[§](#tf0035){ref-type="table-fn"} (10.9)
  Age                                                                     − 71.2[‡](#tf0030){ref-type="table-fn"} (− 2.99)
  Male (1/0)                                                              1093[‡](#tf0030){ref-type="table-fn"} (2.84)
  Intercept                − 334 (− 0.59)                                 8605[§](#tf0035){ref-type="table-fn"} (4.01)
  R^2^ adjusted            0.13                                           0.51

Data were collected between January 2010 and September 2012 in Alberta, Canada.

Based on the original sample.

p-Value \< .05.

p-Value \< .01.

p-Value \< .001.

###### 

Cost--effectiveness analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                          Intervention\   Control\   Difference
                                                          (n = 94)        (n = 92)   
  ------------------------------------------------------- --------------- ---------- ------------------------------------------------------------------------------------
  Cost per participant[a](#tf0040){ref-type="table-fn"}   1176            1172       102[b](#tf0045){ref-type="table-fn"} (− 318, 464)[c](#tf0050){ref-type="table-fn"}

  Average steps per participant                           7038            6645       919[d](#tf0055){ref-type="table-fn"} (116, 1666)[c](#tf0050){ref-type="table-fn"}

  ICER[e](#tf0060){ref-type="table-fn"}                   111                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data were collected between January 2010 and September 2012 in Alberta, Canada.

2011 Canadian dollars.

Adjusted for pre-enrolment cost and body mass index (BMI), see [Table 2](#t0010){ref-type="table"}.

Non-parametric bootstrap 95% confidence interval based on 10,000 replications.

Adjusted for baseline average steps, body mass index (BMI), age and sex, see [Table 2](#t0010){ref-type="table"}.

ICER = incremental cost--effectiveness ratio = additional cost per 1000 steps = incremental cost (102) ∕ incremental outcome (919/1000).
